News & Media
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
With New Validation Data, BillionToOne Boosts Commercial Prospects of Therapy Selection Assay
With New Validation Data, BillionToOne Boosts Commercial Prospects of Therapy Selection Assay
GenomeWeb- BillionToOne Pushing Forward in Cancer Diagnostics With First Data on Response Monitoring Test
GenomeWeb- BillionToOne Pushing Forward in Cancer Diagnostics With First Data on Response Monitoring Test
BioWorld MedTech Interview- BillionToOne test reduces need for Rhogam in 40% of Rh-negative pregnancies
BioWorld MedTech Interview- BillionToOne test reduces need for Rhogam in 40% of Rh-negative pregnancies
BILLIONTOONE MITIGATING RHOGAM(R) SHORTAGE WITH UNITY FETAL RhD™ NON-INVASIVE PRENATAL TEST
BILLIONTOONE MITIGATING RHOGAM(R) SHORTAGE WITH UNITY FETAL RhD™ NON-INVASIVE PRENATAL TEST
BillionToOne is recognized by Forbes as one of America's Best Startup Employers for 2024!
BillionToOne is recognized by Forbes as one of America's Best Startup Employers for 2024!
BILLIONTOONE ANNOUNCES ROSS TAYLOR AS CHIEF FINANCIAL OFFICER
BILLIONTOONE ANNOUNCES ROSS TAYLOR AS CHIEF FINANCIAL OFFICER
BillionToOne to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BillionToOne to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BillionToOne Announces Global Collaboration to Provide its UNITY Fetal Antigen™ Clinical Trial Assay in Johnson & Johnson Phase 3 Clinical Trial of Nipocalimab in Hemolytic Disease of the Fetus and Newborn
BillionToOne Announces Global Collaboration to Provide its UNITY Fetal Antigen™ Clinical Trial Assay in Johnson & Johnson Phase 3 Clinical Trial of Nipocalimab in Hemolytic Disease of the Fetus and Newborn
Social Posts